Newsfeeds Archive - Page 425 of 461

1 minute read

Dynavax’s Adjuvant Based COVID-19 Shot Shows Robust Immune Response, Safety In Younger Populations

August 25, 10:31 AM

Hong Kong-listed Clover Biopharmaceuticals Ltd announced data from a global Phase 2/3 trial evaluating its COVID-19 vaccine candidate, SCB-2019, in adolescents (aged 12 to 17 years).

DVAX

1 minute read

With Sandoz Spinoff, Novartis Slams Brakes On Huntington’s Trial

By Vandana Singh

August 25, 10:12 AM

Novartis AG (NYSE: NVS) suspended dosing in a Huntington's disease study because early signs of side effects were seen in some participants in the trial.

NVS

1 minute read

Phibro Animal Clocks 16% Jump In Q4 Sales, Plans Incremental Strategic Investments In Future

By Vandana Singh

August 25, 9:38 AM

Phibro Animal Health Corp (NASDAQ:PAHC) posted Q4 FY22 sales of $255.3 million, +16% Y/Y, beating the consensus of $246.02 million.…

PAHC

1 minute read

Back-To-Back Three Japanese Approvals For AstraZeneca’s Rare Disease Treatments

By Vandana Singh

August 25, 8:50 AM

The Japan regulatory authority has approved AstraZeneca Plc (NASDAQ:AZN) and Merck Co Inc’s (NYSE:MRK) Lynparza (olaparib) for the adjuvant treatment of patients with…

AZN

1 minute read

Lannett Clocks 30% Top-Line Decline In Q4, Forecasts Lower FY23 Sales

By Vandana Singh

August 25, 8:04 AM

Lannett Company Inc (NYSE:LCI) reported Q4 FY22 sales of $74.2 million, down from $106 million a year ago, slightly below…

LCI

1 minute read

EXCLUSIVE: Longeveron’s Heart Disease Cell Therapy Poised To Secure European Patent

By Vandana Singh

August 25, 7:30 AM

The European Patent Office has issued a notice of its intent to grant Longeveron Inc (NASDAQ: LGVN) a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic mesenchymal cell therapies, also known as medicinal signaling cells (MSCs).

LGVN

1 minute read

What This Analyst Expects From Cooper Companies Q3 Earnings

By Vandana Singh

August 24, 3:39 PM

Needham expects Cooper Companies Inc (NYSE: COO) to miss F3Q22 consensus revenue and EPS estimates due to unfavorable currency, lockdowns in China, and incremental interest expense when it releases earnings next week.

COO

1 minute read

One Analyst Is Bullish On Medtronic, Another Is Not Post Q1 Earnings

By Vandana Singh

August 24, 3:36 PM

Citi says that Medtronic plc (NYSE: MDT) delivered better-than-expected FY1Q23 results, reiterating FY23 guidance despite the ongoing litany of pressures impacting Medtech.

MDT